PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3535405

Physical activity and prostanoids.

R Rauramaa
View original source ↗Export metadata ↓

Abstract

Physical activity plays an important role in the prevention of ischaemic heart disease. However, data on the mediating mechanisms are only partly established, and concentrated mainly on plasma lipoproteins. Prostanoids, especially prostacyclin and thromboxane, through their effects on vascular endothelium, platelet function, and interaction with lipoproteins, are postulated to be centrally involved in the pathogenesis of atherosclerosis. The reported acute effects of physical activity on prostanoids and platelet function are contradictory and may be considered both beneficial and unfavourable. On the other hand, although even less is reported on the response to regular exercise, data appear more favourable in relation to atherosclerosis. Currently, data on physical activity and prostanoids, including both acute and chronic effects, are limited and necessitate additional, systematic studies on dose-response relationships.

Explore related subjects

EpoprostenolHumansMalePhysical ExertionPlatelet AggregationThromboxanesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Rauramaa. 1986. Physical activity and prostanoids.. https://doi.org/10.1111/j.0954-6820.1986.tb08942.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Development of a common fully stereocontrolled access to the medicinally important and promising prostacyclin analogues iloprost, 3-oxa-iloprost and cicaprost.

We describe new fully stereocontrolled syntheses of the prostacyclin analogues iloprost (2), the most active component of the drugs Ilomedin and Ventavis, and 3-oxa-iloprost (3), a derivative that is expected to have a significantly higher metabolic stability than 2 perhaps allowing an oral application. The syntheses are based on the same strategy and chiral bicyclic building block as used in the synthesis of cicaprost (4), the third most potent analogue that exhibits, besides prostacyclin-like activities, antimetastatic activities. Reaction of the enantiopure C6-C13 bicyclic aldehyde 17 with Cl(3)CCOOH/Cl(3)CCOONa afforded trichlorocarbinol 24 which was converted via mesylate 25 to the C6-C14 bicyclic alkyne 9. The palladium-catalysed hydrostannylation of alkyne 9 gave with high regio- and stereoselectivity the alkenylstannane 26, Sn/Li exchange of which afforded the E-configured alkenyllithium derivative 8. Coupling of the C6-C14 building block 8 with the enantiopure C15-C20 building block, the N-methoxyamide 7, gave the C6-C20 bicyclic ketone 6 in high yield without epimerisation at C16. The configuration at C15 of iloprost (2) and 3-oxa-iloprost (3) was established through a highly diastereoselective reduction of ketone 6 with catecholborane and the chiral oxazaborolidine 28 which furnished alcohol (15S)-29. The highly stereoselective conversions of alcohol (15S)-29 to iloprost (2) and 3-oxa-iloprost (3), which include as key stereoselective steps an olefination with a chiral phosphonoacetate and a copper-mediated allylic alkylation, have already been described.

Epoprostenol↗
PubMed2006

Cross metathesis as a general strategy for the synthesis of prostacyclin and prostaglandin analogues.

[reaction: see text] A cross metathesis (CM) approach has been successfully applied to introduce fully functionalized omega-side chain appendages of various prostacyclin and prostaglandin analogues, resulting in high (E)-selectivities for the C13-C14 double bond and leading to the total syntheses of isocarbacyclin, 15R-TIC, carbacyclin, and PGF(2)(alpha) and the formal syntheses of 15-deoxy-TIC and PGJ(2).

Epoprostenol↗